Logo
x

Search

Subscribe Now

NMPA

New Drug Designations - September 2024

New Drug Designations - September 2024

  • October 29, 2024
New Drug Designations - April 2024

New Drug Designations - April 2024

  • May 30, 2024
Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Primary Haemophagocytic Lymphohistiocytosis

Sobi’s Gamifant (emapalumab) Received Recommendation for Approval in China from CDE to Treat Adult and Paediatric Patients with Pr...

  • February 28, 2022
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

  • November 19, 2021
Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large...

  • November 2, 2021
Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

Everest's SPR206 Receives the NMPA's IND Approval for the Treatment of MDR Gram-Negative Bacterial Infections

  • September 24, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.